1887
Research Open Access
Like 0

Abstract

Background

Respiratory syncytial virus (RSV) is a major contributor to lower respiratory tract infections worldwide and several vaccine candidates are currently in development. Following vaccine introduction, reliable RSV surveillance should enable monitoring of vaccination impact. Data on the RSV disease burden in the European Union and European Economic Area (EU/EEA) are sparse.

Aim

The aim of this study was to gather knowledge on current practices of national RSV surveillance in the EU/EEA.

Methods

National Coordinators and National Focal Points for Influenza (epidemiologists and virologists) from the EU/EEA countries (n = 31) were invited to participate in an online survey in August and September 2017. The questionnaire covered questions on epidemiological and laboratory aspects of RSV surveillance.

Results

All EU/EEA countries except Liechtenstein replied to the survey. Eighteen countries reported to have a sentinel surveillance system, 26 countries a non-sentinel surveillance system and three countries to have neither. RSV data collection was mostly done within the context of influenza surveillance. A wide range of diagnostic and characterisation assays was used for the detection of RSV.

Discussion

The majority of EU/EEA countries have some surveillance for RSV in place. The prevailing integration of RSV surveillance into the existing influenza sentinel surveillance system may lead to under-reporting of RSV. The documented variations in existing RSV surveillance systems and their outputs indicate that there is scope for developing guidelines on establishing comparable methods and outcomes for RSV surveillance across the EU/EEA, to ensure the availability of a consistent evidence base for assessing future vaccination programmes.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2019.24.40.1900157
2019-10-03
2019-10-23
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2019.24.40.1900157
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/24/40/eurosurv-24-40-1.html?itemId=/content/10.2807/1560-7917.ES.2019.24.40.1900157&mimeType=html&fmt=ahah

References

  1. Shi T, McAllister DA, O’Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946-58.  https://doi.org/10.1016/S0140-6736(17)30938-8  PMID: 28689664 
  2. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588-98.  https://doi.org/10.1056/NEJMoa0804877  PMID: 19196675 
  3. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545-55.  https://doi.org/10.1016/S0140-6736(10)60206-1  PMID: 20399493 
  4. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749-59.  https://doi.org/10.1056/NEJMoa043951  PMID: 15858184 
  5. Fleming DM, Taylor RJ, Lustig RL, Schuck-Paim C, Haguinet F, Webb DJ, et al. Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect Dis. 2015;15(1):443.  https://doi.org/10.1186/s12879-015-1218-z  PMID: 26497750 
  6. Meijboom MJ, Pouwels KB, Luytjes W, Postma MJ, Hak E. RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population. Vaccine. 2013;31(52):6254-60.  https://doi.org/10.1016/j.vaccine.2013.10.023  PMID: 24148573 
  7. Al-Maskari N, Mohsin J, Al-Maani A, Al-Macki N, Al-Ismaili S. Atypical presentations of respiratory syncytial virus infection: case series. Sultan Qaboos Univ Med J. 2016;16(1):e86-91.  https://doi.org/10.18295/squmj.2016.16.01.016  PMID: 26909220 
  8. Russell CD, Unger SA, Walton M, Schwarze J. The human immune response to respiratory syncytial virus infection. Clin Microbiol Rev. 2017;30(2):481-502.  https://doi.org/10.1128/CMR.00090-16  PMID: 28179378 
  9. Peret TC, Hall CB, Schnabel KC, Golub JA, Anderson LJ. Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J Gen Virol. 1998;79(Pt 9):2221-9.  https://doi.org/10.1099/0022-1317-79-9-2221  PMID: 9747732 
  10. Anderson LJ, Hierholzer JC, Tsou C, Hendry RM, Fernie BF, Stone Y, et al. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis. 1985;151(4):626-33.  https://doi.org/10.1093/infdis/151.4.626  PMID: 2579169 
  11. Yu J, Liu C, Xiao Y, Xiang Z, Zhou H, Chen L, et al. Respiratory syncytial virus seasonality, Beijing, China, 2007-2015. Emerg Infect Dis. 2019;25(6):1127-35.  https://doi.org/10.3201/eid2506.180532  PMID: 31107230 
  12. Midulla F, Nenna R, Scagnolari C, Petrarca L, Frassanito A, Viscido A, et al. How respiratory syncytial virus genotypes influence the clinical course in infants hospitalized for bronchiolitis. J Infect Dis. 2019;219(4):526-34.  https://doi.org/10.1093/infdis/jiy496  PMID: 30204889 
  13. Pierangeli A, Trotta D, Scagnolari C, Ferreri ML, Nicolai A, Midulla F, et al. Rapid spread of the novel respiratory syncytial virus A ON1 genotype, central Italy, 2011 to 2013. Euro Surveill. 2014;19(26):20843.  https://doi.org/10.2807/1560-7917.ES2014.19.26.20843  PMID: 25011065 
  14. Reiche J, Schweiger B. Genetic variability of group A human respiratory syncytial virus strains circulating in Germany from 1998 to 2007. J Clin Microbiol. 2009;47(6):1800-10.  https://doi.org/10.1128/JCM.02286-08  PMID: 19386848 
  15. Martinelli M, Frati ER, Zappa A, Ebranati E, Bianchi S, Pariani E, et al. Phylogeny and population dynamics of respiratory syncytial virus (Rsv) A and B. Virus Res. 2014;189:293-302.  https://doi.org/10.1016/j.virusres.2014.06.006  PMID: 24954788 
  16. Ohuma EO, Okiro EA, Ochola R, Sande CJ, Cane PA, Medley GF, et al. The natural history of respiratory syncytial virus in a birth cohort: the influence of age and previous infection on reinfection and disease. Am J Epidemiol. 2012;176(9):794-802.  https://doi.org/10.1093/aje/kws257  PMID: 23059788 
  17. Sande CJ, Mutunga MN, Okiro EA, Medley GF, Cane PA, Nokes DJ. Kinetics of the neutralizing antibody response to respiratory syncytial virus infections in a birth cohort. J Med Virol. 2013;85(11):2020-5.  https://doi.org/10.1002/jmv.23696  PMID: 23983183 
  18. Pangesti KNA, Abd El Ghany M, Walsh MG, Kesson AM, Hill-Cawthorne GA. Molecular epidemiology of respiratory syncytial virus. Rev Med Virol. 2018;28(2):e1968.  https://doi.org/10.1002/rmv.1968  PMID: 29377415 
  19. Groothuis JR, Hoopes JM, Hemming VG. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis. Adv Ther. 2011;28(2):110-25.  https://doi.org/10.1007/s12325-010-0101-y  PMID: 21318605 
  20. Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017;9(388):eaaj1928.  https://doi.org/10.1126/scitranslmed.aaj1928  PMID: 28469033 
  21. Novavax. Novavax announces topline results from phase 3 PrepareTM trial of ResVax for prevention of RSV disease in infants via maternal immunization. Rockville: Novavax. [Accessed:23 May 2019]. Available from: https://ir.novavax.com/news-releases/news-release-details/novavax-announces-topline-results-phase-3-preparetm-trial
  22. European Centre for Disease Prevention and Control (ECDC). Proceedings of the Workshop on burden of RSV disease in Europe: ECDC Expert Consultation Meeting Stockholm 23–24 November 2015. Stockholm: ECDC; [Accessed: 14 Jul 2018]. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/press/events/Documents/Meeting%20report%20ECDC%20RSV%20surv%20and%20burden%20of%20disease%20workshop%2023-24%20Nov.pdf
  23. PATH. RSV vaccine and mAb snapshot. Vaccine resource library. Seattle: PATH; 2019. Available from: https://vaccineresources.org/details.php?i=1562
  24. Broberg EK, Waris M, Johansen K, Snacken R, Penttinen PEuropean Influenza Surveillance Network. Seasonality and geographical spread of respiratory syncytial virus epidemics in 15 European countries, 2010 to 2016. Euro Surveill. 2018;23(5):17-00284.  https://doi.org/10.2807/1560-7917.ES.2018.23.5.17-00284  PMID: 29409569 
  25. Meerhoff TJ, Fleming D, Smith A, Mosnier A, van Gageldonk-Lafeber AB, Paget WJ, et al. Surveillance recommendations based on an exploratory analysis of respiratory syncytial virus reports derived from the European Influenza Surveillance System. BMC Infect Dis. 2006;6(1):128.  https://doi.org/10.1186/1471-2334-6-128  PMID: 16899110 
  26. Meerhoff TJ, Mosnier A, Schellevis F, Paget WJEISS RSV Task Group. Progress in the surveillance of respiratory syncytial virus (RSV) in Europe: 2001-2008. Euro Surveill. 2009;14(40):19346. PMID: 19822120 
  27. A Hogan C, Caya C, Papenburg J. Rapid and simple molecular tests for the detection of respiratory syncytial virus: a review. Expert Rev Mol Diagn. 2018;18(7):617-29.  https://doi.org/10.1080/14737159.2018.1487293  PMID: 29890085 
  28. Rabon-Stith KM, McGuiness CB, Saunders B, Edelman L, Kumar VR, Boron ML. Laboratory testing trends for respiratory syncytial virus, 2007-2011. J Clin Virol. 2013;58(3):575-8.  https://doi.org/10.1016/j.jcv.2013.09.012  PMID: 24103492 
  29. World Health Organization (WHO). WHO technical meeting on piloting RSV Surveillance based on the Global Influenza Surveillance and Response System. 28-30 June 2016, Geneva, Switzerland. WHO/OHE/PED/GIP/2016.6. Geneva: WHO; 2016. Available from: https://www.who.int/influenza/resources/publications/Technical_Meeting_RSV_Pilot/en/
  30. World Health Organization (WHO). WHO global RSV surveillance pilot - objectives. Geneva: WHO; 2017. Available from: http://www.who.int/influenza/rsv/rsv_objectives/en/
  31. Broor S, Campbell H, Hirve S, Hague S, Jackson S, Moen A, et al. Leveraging the Global Influenza Surveillance and Response System for global respiratory syncytial virus surveillance-opportunities and challenges. Influenza Other Respir Viruses. 2019;irv.12672.; Epub ahead of print.  https://doi.org/10.1111/irv.12672  PMID: 31444997 
  32. Coiras MT, Pérez-Breña P, García ML, Casas I. Simultaneous detection of influenza A, B, and C viruses, respiratory syncytial virus, and adenoviruses in clinical samples by multiplex reverse transcription nested-PCR assay. J Med Virol. 2003;69(1):132-44.  https://doi.org/10.1002/jmv.10255  PMID: 12436489 
  33. Auburn H, Zuckerman M, Broughton S, Greenough A, Smith M. Detection of nine respiratory RNA viruses using three multiplex RT-PCR assays incorporating a novel RNA internal control transcript. J Virol Methods. 2011;176(1-2):9-13.  https://doi.org/10.1016/j.jviromet.2011.05.017  PMID: 21620897 
  34. Meijer A, Benschop KS, Donker GA, van der Avoort HG. Continued seasonal circulation of enterovirus D68 in the Netherlands, 2011-2014. Euro Surveill. 2014;19(42):20935.  https://doi.org/10.2807/1560-7917.ES2014.19.42.20935  PMID: 25358039 
  35. Meijer A, van der Sanden S, Snijders BE, Jaramillo-Gutierrez G, Bont L, van der Ent CK, et al. Emergence and epidemic occurrence of enterovirus 68 respiratory infections in The Netherlands in 2010. Virology. 2012;423(1):49-57.  https://doi.org/10.1016/j.virol.2011.11.021  PMID: 22177700 
  36. Meerhoff TJ, MacKay WG, Meijer A, Paget WJ, Niesters HG, Kimpen JL, et al. The impact of laboratory characteristics on molecular detection of respiratory syncytial virus in a European multicentre quality control study. Clin Microbiol Infect. 2008;14(12):1173-6.  https://doi.org/10.1111/j.1469-0691.2008.02100.x  PMID: 19046164 
  37. Chartrand C, Tremblay N, Renaud C, Papenburg J. Diagnostic accuracy of rapid antigen detection tests for respiratory syncytial virus infection: systematic review and meta-analysis. J Clin Microbiol. 2015;53(12):3738-49.  https://doi.org/10.1128/JCM.01816-15  PMID: 26354816 
/content/10.2807/1560-7917.ES.2019.24.40.1900157
Loading

Data & Media loading...

Supplementary data

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error